Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
RécupérationPréclinique uniquement

KPV

Recherche publiée et base de preuves

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13). Its evidence base is entirely preclinical and is concentrated in gut inflammation, where oral or rectal delivery via the PepT1 di/tripeptide transporter reduces colitis severity in rodent models, and in topical or barrier-protective applications in keratinocytes. A substantial share of the recent literature is formulation science (nanoparticles, hydrogels, microneedles) rather than new pharmacology. There are no human trials of KPV for any indication.

En bref
  • KPV est un tripeptide dérivé de l'hormone alpha-mélanocyte-stimulante.
  • Des études animales ont rapporté une réduction de la colite et des études cellulaires ont examiné les effets sur les kératinocytes.
  • Aucun essai humain n'a été publié pour aucune indication.

17 études · 6 depuis 2023 · plus récente 2026

Études citées
17
Publiées 2023+
6
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • NF-kappaB suppression and cytokine reduction
  • PepT1-mediated intestinal uptake
  • colitis and gut barrier repair
  • keratinocyte protection and skin inflammation
  • antimicrobial activity of alpha-MSH fragments
  • targeted oral and topical delivery systems

Identifiants du composé

CAS
67727-97-3
PubChem
125672

Statut réglementaire

Recommandé par un comité consultatif de la FDA.

Le 23–24 July 2026, le comité consultatif sur la préparation pharmaceutique de la FDA a examiné KPV pour la liste 503A Bulks et a recommandé son ajout lors d'un vote rapporté de 8–6 with one abstention. Heard as KPV free base and KPV acetate, and recommended on a divided vote.

Ce n'est pas une approbation. Le comité conseille ; il ne décide pas. La recommandation n'est pas contraignante, la FDA n'a pas terminé la réglementation qui changerait formellement quoi que ce soit, et l'inclusion dans la liste 503A Bulks n'équivaut pas à l'approbation FDA d'un médicament. La liste régit également la préparation pharmaceutique pour les patients, qui est une activité distincte de la fourniture à usage de recherche uniquement.

Ce que le vote consultatif de juillet 2026 a réellement accompli décrit le processus, les autres composés examinés et les quatre choses que le vote est régulièrement mal interprété comme signifiant.

Identité chimique

Ce qu'est KPV, chimiquement.

Formule moléculaire
C16H30N4O4
Masse moléculaire
342.43 g/mol
Numéro CAS
67727-97-3
PubChem CID
125672

Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.

Les preuves

17 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Animal in vivo2024

    KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy

    Zhang L, et al. · Adv Healthc Mater · carrier-free self-assembled KPV plus rapamycin nanodrug tested in vascular calcification models

    KPV and rapamycin self-assembled into a carrier-free nanodrug that reduced vascular calcification, avoiding the low drug-loading and safety limitations of conventional nanomedicine carriers.

  2. 02Animal in vivo2024

    Growth Factors-Loaded Temperature-Sensitive Hydrogel as Biomimetic Mucus Attenuated Murine Ulcerative Colitis via Repairing the Mucosal Barriers

    Li D, et al. · ACS Appl Mater Interfaces · murine ulcerative colitis treated with a thermosensitive poloxamer hydrogel carrying hyaluronic acid, epigallocatechin-3-gallate, KPV tripeptide and epidermal growth factor

    The KPV-containing biomimetic mucus hydrogel attenuated murine ulcerative colitis by repairing the mucosal barrier.

  3. 03Animal in vivo2021

    Self-Cross-Linked Hydrogel of Cysteamine-Grafted gamma-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats

    Sun J, et al. · ACS Biomater Sci Eng · TNBS-induced ulcerative colitis in rats; rectally administered KPV stabilised in a self-cross-linked thiolated gamma-polyglutamic acid hydrogel

    Free KPV solution was unstable on rectal administration, which compromised efficacy; the hydrogel-stabilised formulation alleviated TNBS-induced colitis in rats.

  4. 04Animal in vivo2021

    In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis

    Shao W, et al. · Biomater Sci · chemotherapy-induced oral mucositis model treated with a temperature-sensitive PLGA-PEG-PLGA hydrogel with epigallocatechin-3-gallate as adhesion enhancer, loaded with KPV

    The KPV-loaded mucoadhesive hydrogel produced anti-inflammatory, antibacterial and reparative effects on chemotherapy-induced oral mucositis.

  5. 05Animal in vivo2017

    Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

    Xiao B, et al. · Mol Ther · murine ulcerative colitis; KPV loaded into hyaluronic acid-functionalised polymeric nanoparticles (~272 nm) given orally

    Hyaluronic acid-functionalised nanoparticles mediated targeted delivery of KPV to inflamed colonic tissue and alleviated ulcerative colitis in mice more effectively than free peptide.

  6. 06Animal in vivo2016

    Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model

    Viennois E, et al. · Cell Mol Gastroenterol Hepatol · AOM/DSS-induced colitis-associated cancer in mice overexpressing human PepT1 in intestinal epithelial cells and in PepT1-knockout mice

    PepT1 expression promoted colitis-associated cancer development, and PepT1-transported KPV reduced inflammation and tumour burden in the murine model.

  7. 07Animal in vivo2013

    Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice

    Schaible EV, et al. · PLoS One · experimental traumatic brain injury in mice; single administration of alpha-MSH(11-13), with POMC, MC1R and MC4R mRNA profiling

    A single dose of the tripeptide attenuated brain damage after experimental traumatic brain injury, with reduced inflammation and apoptosis relative to controls.

  8. 08Animal in vivo2008

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

    Kannengiesser K, et al. · Inflamm Bowel Dis · two murine models of intestinal inflammation, including dextran sodium sulfate colitis

    KPV reduced intestinal inflammation in both murine models, supporting the melanocortin-derived tripeptide as an anti-inflammatory agent independent of the full alpha-MSH sequence.

  9. 09Animal in vivo2008

    PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

    Dalmasso G, et al. · Gastroenterology · human Caco2 intestinal epithelial cells and immune cells in vitro, plus two mouse colitis models

    KPV entered intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter, and this transporter-mediated uptake accounted for its anti-inflammatory effect in mouse colitis. This established the mechanism underlying oral KPV dosing.

  10. 10Animal in vivo2006

    Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide.

    Bonfiglio V, et al. · Exp Eye Res · rabbit mechanical corneal epithelial abrasion model plus rabbit corneal epithelial cells

    Topical KPV accelerated corneal re-epithelialisation (all treated corneas closed at 60 h vs none with placebo); the effect was blocked by the NO synthase inhibitor L-NAME.

  11. 11Animal in vivo2003

    Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides

    Getting SJ, et al. · J Pharmacol Exp Ther · murine crystal-induced peritonitis, comparing KPV with alpha-MSH, the core melanocortin peptide, an MC3/MC4 agonist and a selective MC1R agonist

    Systemic KPV significantly reduced leukocyte accumulation in crystal-induced peritonitis, as did alpha-MSH and the MC3/MC4 agonist, whereas the selective MC1R agonist did not. This separated KPV's anti-inflammatory action from MC1R signalling.

  12. 12In vitro2026

    KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARgamma signaling

    An SH, et al. · Tissue Cell · MDI-induced adipocyte differentiation in 3T3-L1 preadipocytes

    KPV dose-dependently suppressed adipocyte differentiation, with 100 ug/mL reducing Oil Red O staining intensity, through modulation of ROS-mediated AKT/mTORC1/PPARgamma signalling.

  13. 13In vitro2026

    Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway in HepG2 cells

    Lee JY, et al. · Cytotechnology · oleic acid-induced lipid accumulation in HepG2 hepatic epithelial cells

    KPV reduced oleic acid-induced lipid deposition and oxidative damage in HepG2 cells, with effects mapped to ROS-dependent regulation of the PPARgamma pathway and fatty acid synthase expression.

  14. 14In vitro2025

    Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway

    Sung J, et al. · Tissue Cell · human HaCaT keratinocytes exposed to fine particulate matter (PM10)

    PM10 suppressed HaCaT proliferation and induced a pro-inflammatory response; KPV mitigated the resulting apoptosis and inflammation by reducing oxidative stress and modulating MAPK/NF-kappaB signalling.

  15. 15In vitro2000

    Antimicrobial effects of alpha-MSH peptides.

    Cutuli M, et al. · J Leukoc Biol · Staphylococcus aureus and Candida albicans cultures plus human neutrophils

    Alpha-MSH and its C-terminal tripeptide KPV inhibited S. aureus colony formation and reduced C. albicans viability and germ-tube formation across a broad concentration range, an effect linked to increased cAMP; neutrophil killing was not reduced.

  16. 16Revue2025

    Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review

    Adnan SB, et al. · Int J Med Sci · review of tripeptides in wound healing and skin regeneration

    The review summarised how short peptides regulate cell migration, proliferation and differentiation during tissue repair, and noted that optimising outcomes in chronic wounds remains an unmet challenge.

  17. 17Revue2008

    Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases

    Brzoska T, et al. · Endocr Rev · review of alpha-MSH and related tripeptides across melanocortin receptor biology and immune-mediated inflammatory disease

    The review consolidated evidence that alpha-MSH and its C-terminal tripeptides exert protective and anti-inflammatory effects via central and peripheral melanocortin receptors and via direct effects on immune cells. It remains the standard mechanistic reference for KPV.

Limites

Ce que ces preuves n'établissent pas.

No human clinical trial of KPV has been published for colitis, wound healing, skin inflammation or any other indication, so effective human dose, route and safety profile are unknown. Free KPV is unstable in aqueous and rectal administration, which is why most recent work uses engineered delivery vehicles rather than the plain peptide sold to consumers; results from those formulations do not transfer to unformulated KPV.

Questions courantes sur la recherche.

What is KPV?

KPV is a three-amino-acid peptide — lysine, proline, valine — corresponding to residues 11–13 of alpha-melanocyte-stimulating hormone. It is the minimal C-terminal fragment of that hormone shown to retain anti-inflammatory activity in published models.

Why does the literature include oral protocols?

KPV is a substrate for PepT1, the di/tripeptide transporter expressed in intestinal epithelial and immune cells, so it can enter target cells after oral delivery. Colitis studies exploit that route directly.

How does KPV relate to alpha-MSH?

KPV is the C-terminal tripeptide of alpha-MSH. Research interest centres on the fact that it retains anti-inflammatory activity in models while lacking the pigmentary signalling of the full-length hormone, and that part of its effect appears to be independent of classical melanocortin-receptor signalling.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.